Hypopituitarism
Conditions
Interventions
Trade Name: Hydrocortone
Product Name: Hydrocortone
Product Code: N/A
Pharmaceutical Form: Tablet
Concentration unit: mg milligram(s)
Sponsors
Bradford Teaching Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age >18 years ACTH deficiency previously assessed by dynamic testing (eg. insulin stress test). Currently taking replacement with hydrocotisone at optimal replacement dose. prior written informed consent Must be on stable dose of other pituitary replacement hormones where there is documented deficiency. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Subjects requiring systemic steroid therapy Subjects taking high dose hormone replacement therapy or oral contraceptive tablets Subjects who are currenlty pregnant or who have had a recent pregnancy or abortion Subjects with known malignancy Subjects with known coagulopathy Subjects who are currently taking or who have recently taken anticoagulant therapy Asian subjects and patients with diabetes millitus in whom abnormalities of the fibrinolytic system may exist.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare and characterise the effect of different doses of glucocorticoid replacement therapy on fibrinolytic parameters.;Secondary Objective: N/A;Primary end point(s): Changes in fibrinolytic parameters eg. PAI-1, tPA | — |
Countries
United Kingdom
Outcome results
None listed